化疗相关性腹泻的发生机制和治疗策略  

Mechanisms and therapeutic strategies of chemotherapy induced diarrhea

作　　者：方青芳[1] 

机构地区：[1]浙江省肿瘤医院药剂科

出　　处：《中国临床药理学与治疗学》2009年第3期351-355,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：化疗相关性腹泻(chemotherapy-induced diarrhea,CID)是肿瘤患者化疗中常见的并发症,不仅会降低患者的体质和生活质量,严重者导致化疗被迫中断,从而影响疗效。许多化疗药物都可以引起腹泻,其中以氟尿嘧啶类(fluorouracil)和伊立替康(irinotecan,CPT-11)的腹泻发生率最高。本文通过对相关化疗药物(主要是5-FU和CPT-11)引起CID的发生机制和治疗策略进行综述,探讨临床有效防治CID的措施。Chemotherapy induced diarrhea （CID） is one of the most common side effects of chemothera- py, it could not only impair the body constitution and life quality of patients, but also result in chemotherapy interruption and less efficacy. Many chemotherapeutic drugs could induce diarrhea, especially fluorouracil and irinotecan have the highest incidence rates. The article reviews the mechanisms and therapeutic strategies of CID as well as explores the effective clinical treatments for cancer patients suffered with CID.

关 键 词：化疗相关性腹泻 伊立替康 5-FU 机制 治疗策略 

分 类 号：R969[医药卫生—药理学]